Directorate Change (6935E)

TIDMONG

RNS Number : 6935E

Oxford Nutrascience Group PLC

12 April 2011

12 April 2011

Oxford Nutrascience Group plc

("Oxford Nutrascience" or "the Company")

Director Changes

Oxford Nutrascience, the specialty pharmaceutical company using pharmaceutic and drug delivery science to develop advanced medicines, announces the appointment of David Norwood as Non-Executive Chairman of the Company with immediate effect. Marcelo Bravo continues as Chief Technology Officer for the Company.

Mr. Norwood (aged 42), former chief executive of the stockbrokers Beeson Gregory and a former director of Evolution, is the founder of the London Stock Exchange listed company, IP Group plc, which specialises in the development of intellectual property based businesses.

Mr. Norwood is one of the early shareholders in Oxford Nutrascience and his appointment at the Company heralds Mr. Norwood's long-standing commitment to building science based UK businesses and his belief that the Company is now at a point of inflection and poised for significant growth. David is currently Chairman of Retroscreen Virology Limited, Europe's leading specialist virology contract research organisation.

Oxford Nutrascience is developing a strong portfolio of pharmaceutic and drug delivery technologies and is using these to develop novel applications of generic or soon to be off patent active pharmaceutical ingredients. Specifically, the company specialises in formulating products that are easier or more pleasant to take for geriatric or pediatric markets as well as modified release formulations for various clinical benefits. The Company's strategy is now primarily focused on the pharmaceutical sector where a significant number of drugs are now generic and where it is becoming increasingly difficult and expensive to bring new drugs to market.

Nigel Theobald, Chief Executive of Oxford Nutrascience Group plc, commented:

"It is not often that you get to work with someone of David's calibre and it is a strong endorsement of the Company's prospects that he has decided to join as Non-Executive Chairman.

"David's decision to come on board is testament to the exciting opportunities ahead for the Company as we focus on the pharmaceutical sector. The Board very much looks forward to the Company benefitting from his significant experience."

For further information:

www.oxfordnutrascience.com

Oxford Nutrascience Group Plc

Nigel Theobald, Chief Executive [phone]

Mark Way, Investor and Media Relations [phone]

ZAI Corporate Finance (Nominated Adviser)

John Depasquale [phone]

Sarang Shah [phone]

Under Schedule 2, paragraph (g) of the AIM Rules, the following information is disclosed:

Mr. David Robert Norwood has been a director / partner of the following companies and partnerships:

Alexander Mining Plc

Amaethon Limited

Climatelabs Ltd

Energetix (Europe) Limited

EM Petroleum Plc

Green Chemicals Plc

Hatt III General Partner Limited

Ilika Technologies Limited

Invesco Perpetual Aim VCT Plc

IP Group Plc

IP2IPO Limited

IP2IPO Management Limited

IP2IPO Management II Limited

IP2IPO Services Limited

IP Ventures (Scotland) Limited

IP Venture Fund (GP) Limited

Kanyon Plc

Modern Biosciences Plc

Ora Capital Partners Plc

Oxeco Plc

Oxford Nanolabs Limited

Oxford Nutrascience Ltd

Solar Labs Plc

Southampton Asset Management Limited

Summit (Oxford) Limited

Summit Corporation Plc

Techtran Corporate Finance Limited

Techtran Group Limited

Techtran Investments Limited

Techtran Limited

Techtran Services Limited

Thermetica Limited

Top Technology Venture TTV IV G.P. Limited

Mr Norwood currently holds 87,514,300 Ordinary Shares in the Company, equivalent to 17.5 per cent of its issued share capital. Mr Norwood has confirmed that there is no additional information to be disclosed in accordance with Schedule 2, paragraph (g) of the AIM rules.

About Oxford Nutrascience Group Plc

-- Oxford Nutrascience is a speciality pharmaceutical company that uses novel pharmaceutics and drug delivery science to develop advanced medicines that extend the lifecycle of branded generics and soon to be off patent API's.

-- Oxford Nutrascience has developed technology for the use of prebiotic soluble fibres in medicine delivery systems that disperse and solubilise medicines, improve taste and mouth feel, simplify processing and eliminate additives.

-- Development work is currently focused on therapeutic categories including analgesics, bone health, indigestion and multivitamin and mineral supplements.

-- Oxford Nutrascience is establishing partnerships with a number of leading academic centers for pharmaceutics and has a growing number of technologies to apply to branded generics and API's.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAMMGMDDMGGMZM